SCHEDULE: RTW Investments Discloses 6.0% Stake in uniQure N.V.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a 6.0% beneficial ownership stake in uniQure N.V. as of December 31, 2025.

Summary

• RTW Investments, LP and Roderick Wong, M.D. collectively hold 3,711,462 Ordinary Shares of uniQure N.V.
• This represents a 6.0% beneficial ownership stake in the company.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of uniQure N.V.
• The calculation of the percentage is based on 62,291,663 shares outstanding as of November 6, 2025, as reported in uniQure N.V.'s Quarterly Report on Form 10-Q.
• Both RTW Investments and Dr. Wong share voting and dispositive power over all 3,711,462 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable institutional investor like RTW Investments can be interpreted as a vote of confidence in uniQure N.V.'s prospects, particularly given their focus on healthcare and life sciences.

Positives

• A significant institutional investor, RTW Investments, LP, and its Chief Investment Officer, Roderick Wong, M.D., have disclosed a 6.0% beneficial ownership in uniQure N.V., indicating confidence in the company.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Negatives

• No specific negative information regarding uniQure N.V.'s operations or financial performance is disclosed in this ownership filing.

Risks

• No specific risks related to uniQure N.V.'s operations or financial health are detailed in this ownership disclosure.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a 6.0% stake by a specialized healthcare investment firm like RTW Investments in a biotechnology company such as uniQure N.V. often signals a belief in the company's long-term potential, particularly in the gene therapy sector where significant capital and expertise are required for drug development and commercialization.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially influencing share price positively.
• Management: Management may view this as validation of their strategy and operations, potentially leading to increased engagement with the new significant shareholder.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by RTW Investments is a positive signal, this filing alone does not provide sufficient operational or financial details to warrant a 'buy' recommendation. It primarily indicates investor confidence. A 'hold' recommendation is appropriate pending further analysis of uniQure N.V.'s financial performance, pipeline progress, and market conditions.

Keywords

uniQure N.V., RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Institutional Investor, Biotechnology, Gene Therapy, N90064101